Tayside Biorepository
https://www.tissuebank.dundee.ac.uk/?page=main
Tayside Biorepository is an established bio-resource responsible for the provision of a wide range of human tissue from consenting patients in addition to providing a large range services including staining and extraction methods.
Services
- Access to the full pathology archive
- Digital imaging
- Immunohistochemistry - scoring
- Immunohistochemistry - staining
- Tissue micro array creation
- Nucleic acid extraction
Existing samples:
- Fit and well (finding)
- Ischemic heart disease (disorder)
- Malignant neoplasm of endometrium of corpus uteri (disorder)
- Malignant neoplasm of liver (disorder)
- Malignant neoplasm of skin (disorder)
- Malignant tumor of breast (disorder)
- Malignant tumor of colon (disorder)
- Malignant tumor of kidney (disorder)
- Malignant tumor of ovary (disorder)
- Malignant tumor of pancreas (disorder)
- Malignant tumor of stomach (disorder)
- Malignant tumor of urinary bladder (disorder)
- Malignant tumour of oesophagus
- Osteoarthritis of knee (disorder)
Networks
- The Scottish Biorepository Network The NRS Biorepository network provides researchers with efficient managed access to a wide range of high-quality and well characterised tissue from across NHS Scotland for use in research. These include surplus material from diagnostic specimens and surgical procedures either from existing collections or through facilitating collection of the required material.
- Confederation of Cancer Biobanks The NCRI’s Confederation of Cancer Biobanks (CCB) is a consortium of biobanks and biosample collections based in the UK, established to encourage greater coordination and promote harmonisation between biobanks – enabling them to share best practice and raise awareness of their collections with researcher
Contact Information
- Email:
- s.i.king@dundee.ac.uk
- Address:
-
TASC
Medical School
Ninewells Hospital & Medical School
Dundee
Angus
DD1 9SY
Scotland
Annual Statistics
Year | Access Requests Received | Access Requests Approved | ||||
---|---|---|---|---|---|---|
Internal | External | Commercial | Internal | External | Commercial | |
2015 | N/A | N/A | N/A | N/A | N/A | N/A |
2016 | N/A | N/A | N/A | N/A | N/A | N/A |
2017 | N/A | N/A | N/A | N/A | N/A | N/A |
2018 | N/A | N/A | N/A | N/A | N/A | N/A |
2019 | N/A | N/A | N/A | N/A | N/A | N/A |
2020 | N/A | N/A | N/A | N/A | N/A | N/A |
2021 | N/A | N/A | N/A | N/A | N/A | N/A |
2022 | N/A | N/A | N/A | N/A | N/A | N/A |
2023 | N/A | N/A | N/A | N/A | N/A | N/A |
2024 | N/A | N/A | N/A | N/A | N/A | N/A |